Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Anecortave acetate: a novel angiostatic steroid for the treatment of ocular neovascular diseases

Aug. 4, 1999

Beta-blocker proxodolol, a safe and effective treatment for glaucoma

Aug. 4, 1999

Travoprost is safe and effective in treating elevated IOP in glaucoma patients

Aug. 3, 1999

Allergan profiles its Ocular Hypotensive Lipids at SOE 1999

Aug. 3, 1999

Alcon describes therapeutic potential of ocular antiinflammatory agents

Aug. 3, 1999

Acadia licenses novel leads for glaucoma therapy to Allergan

July 30, 1999

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

July 29, 1999

New agents for glaucoma disclosed by Alcon in recent patent literature

July 27, 1999

Sunrise LTK System not recommended for FDA approval

July 26, 1999

Alcon's new prostaglandin analogues for glaucoma

July 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 18, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 18, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...